Naoki Nakao

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

Ryohei Katayama, Bo Gong, Noriko Togashi et al. · Nature Communications · 2019 · 135 citations · Full text

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw et al. · Clinical Cancer Research · 2020 · 103 citations · Full text

Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

Taiji Goto, Akiko Shiina, Toshiharu Yoshino et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 37 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Biochemistry +10

Natural ligand-nonmimetic inhibitors of the lipid-transfer protein CERT

Naoki Nakao, Masaharu Ueno, Shota Sakai et al. · Communications Chemistry · 2019 · 35 citations · Full text

Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors

Taiji Goto, Akiko Shiina, Takeshi Murata et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 34 citations · Full text

Combinatorial Chemistry, Biochemistry, Medicine +6